Navigation Links
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
Date:6/17/2009

ible will be treated with Doxil(R) (pegylated liposomal doxorubicin), an approved drug used to treat ovarian cancer, or with EC145, which combines Doxil with folate (vitamin B-9).

The PRECEDENT study is yet another example of CTCA's commitment to expanding medical treatment options for women battling ovarian cancer. In October 2008, CTCA at Midwestern Regional Medical Center announced a ground-breaking clinical trial of an ovarian cancer vaccine called o-Vax that uses cells taken from an individual patient's tumor to stimulate immune cells to attack the existing cancer. Patients continue to be accepted for this clinical trial.

"CTCA offers a powerful combination of traditional and innovative therapies provided by a team of cancer experts who work with each patient individually, to determine the appropriate combination of therapies to fight cancer," Dr. Williams says.

Ovarian cancer is the ninth most common cancer among women, and the leading cause of death due to cancer of the female reproductive system. According to the American Cancer Society, it is estimated that there will be 21,550 new cases of ovarian cancer in the U.S. in 2009 and 14,600 cancer-related deaths. A woman's risk of getting invasive ovarian cancer during her lifetime is about one out of every 71 women.

Patients interested in the clinical trial may contact a CTCA Oncology Information Specialist at 877-98-TRIAL.

About Cancer Treatment Centers of America

Founded in 1988, Cancer Treatment Centers of America (CTCA) provides a comprehensive, patient-centered treatment model that fully integrates traditional, state-of-the-art medical treatments with scientifically-supported complementary and alternative therapies such as nutrition, naturopathy, psychological counseling, physical therapy and spiritual support to meet
'/>"/>

SOURCE Cancer Treatment Centers of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
2. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
3. Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
4. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
5. Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
6. Advance in Bowel Cancer Test Research
7. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
8. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
9. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
10. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
11. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Quietly, sedately, Morocco,s pharmaceutical ... domestic pharmaceutical industry is strong, with a well-developed base ... international standards. One place where the quality ... Africa: Morocco has quietly become the second largest African ... . Indeed, Moroccan pharma companies have been making ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... YORK, Oct. 6, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiry ... Impact Dyslipidemia Market Value ...
... NEW YORK, Oct. 6, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0254328/The-Future-of-European-Pharmaceutical-Distribution.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... to reduce internal costs for manufacturers, and ...
Cached Medicine Technology:Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 2Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 3Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 4Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 5Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 6Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 7Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 8Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 9Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 10Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 11Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 12Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 13Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 14Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 15The Future of European Pharmaceutical Distribution 2The Future of European Pharmaceutical Distribution 3The Future of European Pharmaceutical Distribution 4The Future of European Pharmaceutical Distribution 5The Future of European Pharmaceutical Distribution 6The Future of European Pharmaceutical Distribution 7The Future of European Pharmaceutical Distribution 8The Future of European Pharmaceutical Distribution 9
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed ... Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . ... migration of their Implanon® implants, inability to locate the implants, unsuccessful and invasive ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor ... out of the window, he recalled that his equipment was set up to depict the ... he jumped out of bed. , The photo speaks for itself. Chatfield is also a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels of ... study published today in Nature Communications and led by researchers from the Icahn School ... variations in the gene RTN1 led to greater production of the related RNT1 protein, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2
... Center have found a new technique that employs RNA, a ... lead to therapeutics// for conditions in which nudging a gene ... with a novel research tool to investigate the role that ... paper appearing online at Nature Chemical Biology and in an ...
... right type of fat may actually keep child obesity at ... unsaturated fat and very little omega-3. ,A study ... was undertaken by scientists at Goteborg University. These children belong ... revealed that 23% of the children belong to an overweight ...
... MPs, members of the Committee of Public Accounts, has come out ... ,Levels of obesity in children aged two to 10 years ... 2004, according to the Health Survey for England. , ... as obese. ,The Public Accounts Committee report ...
... Boston ranked the top city in America for having a ... conducted by Fit Pregnancy magazine, Boston’s outstanding// healthcare resources is ... like low birth risks and family recreation. The magazine shared ... Wednesday. ,Mayor Thomas M. Menino, while commenting on ...
... study finds that CT scans used in emergency rooms spotted ... MRI scans which are better in identifying any type of ... to magnetic resonance imaging,” wrote Dr. Geoffrey A. Donnan and ... note accompanying the study report. ,Doctors argue that ...
... project to revamp its healthcare infrastructure and train health ... expected to benefit over 45 million people. ,Health ... medical facilities at the village level and the project ... scheme would benefit over 45 million people at the ...
Cached Medicine News:Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:Under-Elevens Hurtle Towards Obesity, British MPs Call for Action 2Health News:Mega Project to Revamp Karnataka’s Healthcar 2
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: